|
|
Volumn 537, Issue 7620, 2016, Pages S106-S108
|
|
Targeted therapy: An elusive cancer target
a
a
NONE
(Canada)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AXITINIB;
BEVACIZUMAB;
CABOZANTINIB;
EVEROLIMUS;
LENVATINIB;
PAZOPANIB;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BLOOD;
CANCER;
CHEMOTHERAPY;
DRUG DEVELOPMENT;
MEDICINE;
SURVIVAL;
ADVANCED CANCER;
ANGIOGENESIS;
ARTICLE;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
CANCER HORMONE THERAPY;
CANCER RECURRENCE;
CANCER RESISTANCE;
CANCER RISK;
CANCER STAGING;
CANCER SURVIVAL;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE QUALITY;
HUMAN;
KIDNEY CANCER;
KIDNEY CARCINOMA;
MEDICAL ONCOLOGIST;
METASTATIC COLON CANCER;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
SURVIVAL RATE;
VASCULARIZATION;
ADVERSE EFFECTS;
CARCINOMA, RENAL CELL;
CLINICAL TRIAL (TOPIC);
ENZYMOLOGY;
GENETICS;
IMMUNOLOGY;
IMMUNOTHERAPY;
KIDNEY NEOPLASMS;
MOLECULARLY TARGETED THERAPY;
NEOVASCULARIZATION, PATHOLOGIC;
PATHOLOGY;
PREVENTION AND CONTROL;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
TUMOR RECURRENCE;
FRANCE;
ILE DE FRANCE;
PARIS;
VILLE DE PARIS;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS AS TOPIC;
HUMANS;
IMMUNOTHERAPY;
KIDNEY NEOPLASMS;
MOLECULAR TARGETED THERAPY;
NEOPLASM RECURRENCE, LOCAL;
NEOVASCULARIZATION, PATHOLOGIC;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 84987851407
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/537S106a Document Type: Article |
|
Times cited : (55)
|
|
References (4)
|
